• In late June 2026, CoreWeave launched ARIA, an AI research agent embedded in Weights & Biases that automates experiment analysis and model iteration, while expanding its AI cloud footprint in Europe through new renewable-powered data center capacity and a multi-exabyte storage deal with Backblaze.
• At the same time, reports that Meta Platforms plans to sell its own excess AI compute capacity have raised fresh questions about CoreWeave’s dependence on major customers and its position in an increasingly crowded AI infrastructure market.
• We’ll now examine how Meta’s move into selling excess AI compute, alongside CoreWeave’s ARIA launch, could reshape its investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

CoreWeave Investment Narrative Recap

To own CoreWeave today, you have to believe that demand for third party AI infrastructure and tools like ARIA will stay strong enough to support its heavy spending and large backlog. The key near term catalyst remains how quickly that US$99 billion backlog converts to revenue, while the biggest risk is still its leveraged balance sheet. Meta’s plan to sell excess AI compute intensifies competitive concerns but does not yet fundamentally change those two focal points.

The most relevant recent announcement is ARIA’s launch inside Weights & Biases, which pushes CoreWeave further up the stack from raw GPUs into software and workflow tooling. Against worries that Meta could pressure pricing for basic compute, ARIA highlights a different possible path for value creation: charging for capabilities that help teams run, analyze and improve AI experiments more efficiently on top of CoreWeave’s cloud.

Yet beneath the product headlines, investors should also be aware of CoreWeave’s growing debt load and what happens if AI demand or pricing weakens…

CoreWeave's narrative projects $26.9 billion revenue and $1.6 billion earnings by 2028. This requires 84.2% yearly revenue growth and a $2.4 billion earnings increase from $-824.7 million today.

Uncover how CoreWeave's forecasts yield a $133.12 fair value, a 55% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already worried that CoreWeave’s debt fueled build out could backfire even while projecting US$32.4 billion of 2029 revenue, so Meta’s move and ARIA’s launch may prompt you to revisit how confident you feel in those more cautious assumptions.

Explore 50 other fair value estimates on CoreWeave - why the stock might be worth over 7x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CoreWeave research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free CoreWeave research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CoreWeave's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.